Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated safety profile; Phase 2 trials begin Q2 2026. Secondary asset OV4071, now in Phase 1, pivots toward the lucrative schizophrenia/psychosis market, offering pipeline diversification.
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions
Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and pharmacologic profile versus first-generation Sabril, targeting rare epilepsies. Phase 2 expansion includes POC studies in photosensitive seizures, treatment-resistant FOS, TSC-associated seizures, and infantile spasms, with key catalysts in 2026-2027.
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical research. The clinical-stage biotechnology company said the award highlights a multiyear partnership aimed at incorporating the lived experiences of clinical trial participants into the development of mental health treatments.
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years.
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.13 per share a year ago.
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
